The MAP 2023 programme is now online!
The Molecular Analysis for Precision Oncology Congress 2023 (MAP) is the leading global meeting dedicated to precision oncology and translational research. This oncology field is fast evolving and has now entered the mainstream of clinical practice.
By attending MAP, participants will gain deeper insights into precision medicine, cancer-stromal interactions, clonal evolution, metastatic dissemination and drug response and resistance.
Additionally, a special “RoadMAP to the Clinic” day will cover more clinically-oriented aspects related to new concepts of molecular tumour classification and biomarker-driven drug development.
- Provide up-to-date information on the molecular characterisation and clonal evolution of solid tumours on different cancer populations
- Understand emerging technologies for cancer profiling, including artificial intelligence and data analysis
- Acquire a better understanding of mechanisms driving tumour expansion, metastatic dissemination and cross talk between malignancy, microenvironment and host
- Learn about new concepts of molecular tumour classification and biomarker-driven development of targeted therapeutics with their methodological and regulatory implications
ESMO-MORA: The MAP Congress programme has been accredited with 20 ESMO-MORA Cat. 1 points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. It also guarantees that a certified medical oncologist has continued to update her/his knowledge and still possesses the necessary skills and standards for the practice of medical oncology. See here for further details.
All Speakers and Discussants are required to declare their interests, if any, and include a Declaration of Interest (DOI) slide at the start of their presentation(s).
The experts invited by ESMO as Discussants are selected on an individual basis to provide their own interpretation of the data and are not acting as ESMO spokespersons.
The ESMO recommendations on the clinical utility of new drugs are only presented in the ESMO Clinical Practice Guidelines and such recommendations represent the only official position of ESMO.